Posted by Michael Wonder on 27 Jul 2022
MSAC publishes agenda for November 2022 meeting
27 July 2022 - 12 agenda items for consideration at the 24-25 November 2022 meeting.
The assessments of note are:
- Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
- KRAS G12C variant testing in patients with locally advanced or metastatic non-small-cell lung cancer to determine eligibility for sotorasib as second-line therapy
- PD-L1 immunohistochemistry testing in patients with persistent, recurrent, or metastatic cervical cancer to determine eligibility for pembrolizumab
- Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia
Read MSAC agenda
Posted by:
Michael Wonder